StockIQpro
NASDAQ:NAMS

NewAmsterdam Pharma Co N.V.

Track all markets on TradingView
Track all markets on TradingView

NewAmsterdam Pharma Co N.V.'s revenue fell 50.6% in fiscal 2025 to $22.5M while operating margin fell to −1002.9%. Free cash flow was −$148.0M, −657.8% of revenue, and the diluted share count rose 25.5%.Summary generated from NewAmsterdam Pharma Co N.V.'s SEC filings. Latest annual report filed Feb 18, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$22.5M
Revenue growth−50.6%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−1002.9%
Net margin−905.7%
ROICn/a
Return on equity−28.3%
Debt / equityn/a
Free cash flow−$148.0M
FCF margin−657.8%
Share count change+25.5%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/a103144623
Operating income−35−4−183−176−226
Net income−42−23−177−242−204
Free cash flow−3010−141−159−148

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations